SCHEMBL171194

SCHEMBL171194

CNC(=O)c1cc(Oc2ccc(CNC(=O)Nc3cc(OC)c(Cl)cc3OC)cc2)ccn1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDR2 Q16832 4/20 0.67
RAF1 P04049 12/20 0.56
GSK3B P49841 2/20 0.53
CSF1R P07333 2/20 0.51
MAPK14 Q16539 3/20 0.49
BRAF P15056 4/20 0.49
KDR P35968 4/20 0.49
EPHX2 P34913 4/20 0.49
RIPK2 O43353 2/20 0.49
ABCB11 O95342 2/20 0.49
ABL1 P00519 2/20 0.49
RET P07949 2/20 0.49
HTR1A P08908 2/20 0.49
PDGFRB P09619 2/20 0.49
ADORA3 P0DMS8 2/20 0.49
KIT P10721 2/20 0.49
FGFR1 P11362 2/20 0.49
PDGFRA P16234 2/20 0.49
FLT1 P17948 2/20 0.49
MAOA P21397 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13603633 0.93 DDR2 (0.70) DDR2RAF1GSK3BCSF1RMAPK14
SCHEMBL171217 0.91 DDR2 (0.70) DDR2RAF1GSK3BCSF1RMAPK14
SCHEMBL15574618 0.91 DDR2 (0.55) DDR2RAF1GSK3BKMT2AALDH1A1
SCHEMBL171051 0.90 RAF1 (0.71) DDR2RAF1GSK3BCSF1RMAPK14
SCHEMBL13603632 0.89 DDR2 (0.72) DDR2RAF1GSK3BCSF1RMAPK14
SCHEMBL15574169 0.89 DDR2 (0.82) DDR2RAF1GSK3BCSF1RMAPK14
SCHEMBL17000011 0.89 DDR2 (0.69) DDR2RAF1GSK3BCSF1RMAPK14
SCHEMBL15574556 0.88 DDR2 (0.70) DDR2RAF1CSF1RMAPK14BRAF
SCHEMBL15573355 0.88 DDR2 (0.62) DDR2RAF1GSK3BCSF1RMAPK14
SCHEMBL13603494 0.87 DDR2 (0.61) DDR2RAF1GSK3BCSF1RMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150225369-A1 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS MERCK PATENT GMBH (DE) 2015-08-13 US claimed
EP-2890380-A2 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS Merck Patent GmbH (DE) 2015-07-08 EP claimed
WO-2014032755-A2 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS MERCK PATENT GMBH (DE) 2014-03-06 WO claimed
US-20150225369-A1 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS MERCK PATENT GMBH (DE) 2015-08-13 US disclosed
US-20150225369-A1 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS MERCK PATENT GMBH (DE) 2015-08-13 US disclosed
EP-2890380-A2 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS Merck Patent GmbH (DE) 2015-07-08 EP disclosed
WO-2014032755-A2 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS MERCK PATENT GMBH (DE) 2014-03-06 WO disclosed
US-20130158076-A1 Methylene Urea Derivatives MERCK PATENT GMBH (DE) 2013-06-20 US disclosed
US-8410143-B2 Methylene urea derivatives MERCK PATENT GMBH (DE) 2013-04-02 US disclosed
US-8410143-B2 Methylene urea derivatives MERCK PATENT GMBH (DE) 2013-04-02 US disclosed
EP-2426122-A1 Methylene urea derivative as RAF kinasse inhibitors Merck Patent GmbH (DE) 2012-03-07 EP disclosed
US-20090298885-A1 METHYLENE UREA DERIVATIVES MERCK PATENT GMBH (DE) 2009-12-03 US disclosed
US-20090298885-A1 METHYLENE UREA DERIVATIVES MERCK PATENT GMBH (DE) 2009-12-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298885-A1 METHYLENE UREA DERIVATIVES BRAF, RAF1, CMPK1 DDR2 4558/4885RAF1 2/4885GSK3B 1104/4885
US-20150225369-A1 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS DDR2, DDR1, DDRGK1 DDR2 1/4885RAF1 3072/4885GSK3B 494/4885
US-20130158076-A1 Methylene Urea Derivatives BRAF, RAF1, CMPK1 DDR2 4558/4885RAF1 2/4885GSK3B 1104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.